Skye Bioscience (SKYE) Other financing activities (2018 - 2024)

Skye Bioscience (SKYE) has reported Other financing activities for 6 consecutive years, with $85.7 million the latest figure, recorded in Q1 2024.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $85.7 million in Q1 2024; TTM through Mar 2024 was $85.7 million, a 4354886.12% increase from a year earlier, with the FY2025 full-year figure at $29571.0, up 426.36% from the prior year.
• Other financing activities was $85.7 million for Q1 2024 at Skye Bioscience, up from -$276879.0 in the prior quarter.
• Over five years, Other financing activities peaked at $85.7 million in Q1 2024 and troughed at -$276879.0 in Q3 2023.
• A 5-year average of $10.7 million and a median of $48533.0 in 2020 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities tumbled 141.12% in 2022 and surged 14482.56% in 2023, its largest moves.
• Over 5 years, Other financing activities stood at $48533.0 in 2020, then surged by 14313.32% to $7.0 million in 2021, then sank by 100.03% to -$1967.0 in 2022, then slumped by 13976.21% to -$276879.0 in 2023, then surged by 31035.04% to $85.7 million in 2024.
• The last three Other financing activities figures came in at $85.7 million (Q1 2024), -$276879.0 (Q3 2023), and $282905.0 (Q2 2023), per Business Quant data.